Alizapride
From Wikipedia, the free encyclopedia
 |
|
|
Alizapride
|
|
| Systematic (IUPAC) name | |
| N-[(1-allylpyrrolidin-2-yl)methyl]-6-methoxy- 1H-benzotriazole-5-carboxamide |
|
| Identifiers | |
| CAS number | |
| ATC code | A03 |
| PubChem | |
| Chemical data | |
| Formula | C16H21N5O2 |
| Mol. mass | 315.37 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 3 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral, intramuscular, intravenous |
Alizapride is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide.[1]
Alizapride is marketed under various trade names including Plitican, Superan and Vergentan.[2]
[edit] References
- ^ Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M (1988). "Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial". Cancer Chemother Pharmacol 22 (4): 316–20. PMID 3048762.
- ^ (French) Alizapride Chlorhydrate. BIAM (June 2, 1997). Retrieved on 2007-08-14.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||
